Clinical Trials Logo

Clinical Trial Summary

This study evaluates the use of AMAG-423 (Digoxin Immune Fab) in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03008616
Study type Interventional
Source AMAG Pharmaceuticals, Inc.
Status Terminated
Phase Phase 2/Phase 3
Start date April 12, 2017
Completion date August 13, 2020

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03744988 - Serum Androgen Levels as a Marker for the Severity of Preeclampsia
Completed NCT02189148 - First-trimester Prediction of Preeclampsia
Recruiting NCT04058405 - Risk Prediction Models for Adverse Maternal and Neonatal Outcomes in Preeclampsia
Completed NCT03164304 - Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia Phase 4
Completed NCT02379832 - Pre-Eclampsia And Growth Restriction: a Longitudinal Study
Not yet recruiting NCT01538121 - Antiphospholipid Antibodies and Early Severe Preeclampsia. N/A
Recruiting NCT01906567 - İs There a Relationship Between Severity of Preeclampsia and Maternal Heavy Metal Levels? N/A
Recruiting NCT01382732 - Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia Phase 3
Not yet recruiting NCT04725812 - Complement Regulation to Undo Systemic Harm in Preeclampsia Phase 2
Completed NCT01408979 - Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia Phase 4
Completed NCT01538147 - Restless Leg Syndrome and Severe Preeclampsia N/A